Tofacitinib is used to treat rheumatoid arthritis and it is known that tofacitinib can increase the expression of pro-inflammatory mediators, including PGE2, in macrophages by acting inhibitory on the expression of anti-inflammatory IL-10 (Kothari et al., 2014). The gene discussed is IL10; the disease is rheumatoid arthritis.